October 28, 2008
PARI Respiratory Releases Results of Study Comparing Nebulizers Delivering Budesonide at CHEST 2008
MIDLOTHIAN, Va., Oct. 28 /PRNewswire/ -- Today, PARI Respiratory Equipment presented a comparative study of three commercially available, breath-enhanced nebulizers and their in-vitro performance and delivery efficiency of budesonide inhalation suspension (Pulmicort Respules, AstraZeneca). Conclusions from the in-vitro study show that the LC Sprint Reusable Nebulizer delivered the shortest treatment times, with an average of 4.9 minutes, and had the highest respirable drug delivery rate.
"We found that drug delivery differs between commercially available nebulizers, something for clinicians to consider when contemplating whether patients receive clinically effective doses," said Lisa Cambridge, director of clinical development for PARI Respiratory Equipment, Inc. "Since patient compliance may be associated with the speed of treatment and delivery efficiency, this study highlights key differences between nebulizers."The study compares the LC Sprint Reusable Nebulizer (PARI Respiratory Equipment), LC PLUS Reusable Nebulizer (PARI Respiratory Equipment), and Sidestream Plus reusable nebulizer (Respironics). Ms. Cambridge presented the results today at CHEST 2008, the annual meeting of the American College of Chest Physicians.
Key conclusions showed:
-- Respirable drug delivery rate (RDDR) was the highest with LC Sprint Reusable Nebulizer -- in fact, RDDR is 46% higher for LC Sprint Reusable Nebulizer compared to Sidestream Plus
-- Respirable dose is similar with LC Sprint and LC PLUS, though RDDR was 25% higher for LC Sprint Reusable Nebulizer
-- Respirable dose and RDDR for LC PLUS Reusable Nebulizer demonstrate higher delivery efficiency (33% and 39% respectively) than Sidestream Plus
-- Treatment times were shortest with LC Sprint Reusable Nebulizer (4.9 minutes)
These conclusions draw upon results from an American Thoracic Society poster (Keller M et al., 2002) that show higher respirable drug delivery rate (RDDR) indicates more drug delivery to the lower airway per minute.
About PARI Respiratory Equipment, Inc.
PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them.
Maker of the world's leading breath-enhanced reusable nebulizer, the PARI LC PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufactures the award winning PARI TREK S compact compressor, Bubbles the Fish II aerosol mask, and durable PARI PRONEB Ultra II. PARI's Vortex anti-static valved holding chamber improves the aerosol deposition of metered dose inhalers (MDI's). PARI's North American headquarters is in Midlothian, VA with worldwide headquarters in Starnberg, Germany. Online at http://www.pari.com/
Additional information is available by contacting Ayars & Associates at 805-845-5682 or at 804-253-7274 x711.
PARI Respiratory Equipment, Inc.
CONTACT: Ayars & Associates, +1-805-845-5682, or +1-804-253-7274, ext.711, for PARI Respiratory Equipment, Inc.
Web site: http://www.pari.com/